CMRX Brincidofovir Selected For Use In Ebola Clinical Trial; AZN And ISIS To Co-Develop Targeted Oligonucleotide Delivery Methods

CMRX announced its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study with ebola. (ISIS) and (AZN) announced a strategic alliance to develop novel delivery methods for antisense oligonucleotides.